Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and
meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as
determined by immunohistochemistry. This is a "phase 0" PK (pharmacokinetic) and PD
(pharmacodynamic) study of RAD001 in patients with Neurofibromatosis Type 2-related and
sporadic VS and meningiomas. Enrolled patients will take RAD001 prior to a scheduled VS or
meningioma surgery, and blood and tissue samples will be obtained for further analysis.
Phase:
Early Phase 1
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health